All In Biotech

Drug Trial Radar · NCT06280716

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Apr 24, 2024

Primary completion

Sep 25, 2025

Study completion Jul 16, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.

Conditions

  • Atopic Dermatitis

Interventions

  • PlaceboDrug

    Subcutaneous injection

  • LebrikizumabDrug

    Subcutaneous injection

  • Topical CorticosteroidDrug

    Topical Corticosteroid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Week 16
  2. Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)Time frame: Baseline, Week 16

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Of Fujian Medical University

    Fuzhou, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Wannan Medical College Yijishan Hospital

    Wuhu, Anhui, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Beijing Children's hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital Affiliate of Capital University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tongren Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • The Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Zhongshan Hospital Fudan University (Xiamen Branch)

    Xiamen, Fujian, China

  • Guangdong Province Dermatology Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The University of Hong Kong-Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Hospital of Wuhan

    Wuhan, Hubei, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Children's Hospital

    Changsha, Hunan, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Wuxi No.2 People's Hospital

    Wuxi, Jiangsu, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Children's Hospital of Shanxi

    Taiyuan, Shanxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • The First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China

  • The first Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.